(Q33392997)

26 July 2017

title

Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data (English)

1 reference

26 July 2017

1 reference

Makiko Kusama

1

1 reference

26 July 2017

Kazuya Maeda

2

1 reference

26 July 2017

Koji Chiba

3

1 reference

26 July 2017

Akinori Aoyama

4

1 reference

26 July 2017

Yuichi Sugiyama

5

1 reference

26 July 2017

publication date

12 December 2008

1 reference

26 July 2017

published in

Pharmaceutical Research

1 reference

26 July 2017

volume

26

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

822-835

1 reference

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-008-9781-2

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

21 January 2018

1 reference

12 December 2020

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers

1 reference

12 December 2020

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

1 reference

12 December 2020

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

1 reference

12 December 2020

Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity

1 reference

12 December 2020

Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

1 reference

12 December 2020

ADMET in silico modelling: towards prediction paradise?

1 reference

12 December 2020

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes

1 reference

12 December 2020

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

1 reference

12 December 2020

Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

1 reference

12 December 2020

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

1 reference

12 December 2020

Differential activation of CYP2C9 variants by dapsone

1 reference

12 December 2020

In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

1 reference

12 December 2020

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

12 December 2020

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

1 reference

12 December 2020

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

1 reference

12 December 2020

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide

1 reference

12 December 2020

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

1 reference

12 December 2020

Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure

1 reference

12 December 2020

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

1 reference

12 December 2020

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

1 reference

12 December 2020

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example

1 reference

12 December 2020

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

1 reference

12 December 2020

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

1 reference

12 December 2020

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

1 reference

12 December 2020

Clinical pharmacokinetics of anticonvulsants

1 reference

12 December 2020

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Allelic and functional variability of cytochrome P4502C9.

1 reference

12 December 2020

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

1 reference

12 December 2020

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

1 reference

12 December 2020

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology

1 reference

12 December 2020

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism

1 reference

12 December 2020

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

1 reference

12 December 2020

Pharmacokinetics of phenprocoumon

1 reference

12 December 2020

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

1 reference

12 December 2020

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

1 reference

12 December 2020

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

1 reference

12 December 2020

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

1 reference

12 December 2020

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor

1 reference

12 December 2020

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

12 December 2020

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

12 December 2020

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

1 reference

12 December 2020

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

1 reference

12 December 2020

Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices

1 reference

12 December 2020

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4

1 reference

12 December 2020

Role of CYP2C9 polymorphism in losartan oxidation

1 reference

12 December 2020

Disposition of flurbiprofen in man: influence of stereochemistry and age

1 reference

12 December 2020

Metabolic fate of phenprocoumon in humans

1 reference

12 December 2020

Pharmacogenetics of tolbutamide metabolism in humans

1 reference

12 December 2020

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

12 December 2020

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application

1 reference

12 December 2020

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

1 reference

12 December 2020

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

12 December 2020

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

1 reference

12 December 2020

No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.

1 reference

12 December 2020

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide

1 reference

12 December 2020

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes

1 reference

12 December 2020

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

12 December 2020

Predicting in vivo drug interactions from in vitro drug discovery data

1 reference

12 December 2020

Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

12 December 2020

Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication

1 reference

12 December 2020

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

12 December 2020

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

1 reference

12 December 2020

Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles

1 reference

12 December 2020

Bioavailability of diclofenac potassium at low doses

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans

1 reference

12 December 2020

Biotransformation of Diclofenac Sodium (Voltaren®) in Animals and in Man.: II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments

1 reference

12 December 2020

Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms

1 reference

12 December 2020

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

12 December 2020

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

1 reference

12 December 2020

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

1 reference

12 December 2020

Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport

1 reference

12 December 2020

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

12 December 2020

Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide

1 reference

12 December 2020

Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion.

1 reference

12 December 2020

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

1 reference

12 December 2020

Bioavailability of phenytoin on single and multiple oral doses of two dosage forms in normal subjects

1 reference

12 December 2020

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

1 reference

12 December 2020

Genetic analysis of the human cytochrome P450 CYP2C9 locus

1 reference

12 December 2020

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

1 reference

12 December 2020

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

1 reference

12 December 2020

Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac

1 reference

12 December 2020

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

1 reference

12 December 2020

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

12 December 2020

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

12 December 2020

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

1 reference

12 December 2020

Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking C

1 reference

12 December 2020

10.1007/S11095-008-9781-2

Identifiers

DOI

1 reference

26 July 2017

1 reference